In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen 5,DTrp 7,Dab 8]urotensin II(4-11) (UFP-803)

British Journal of Pharmacology

Volumn 147, Issue 1, 2006, Pages 92-100

  Camarda, Valeria ^a   Spagnol, Martina ^a   Song, Wei ^b   Vergura, Raffaella ^a   Roth, Adelheid L ^c   Thompson, Jonathan P ^b   Rowbotham, David J ^b   Guerrini, Remo ^a   Marzola, Erika ^a   Salvadori, Severo ^a   Cavanni, Paolo ^c   Regoli, Domenico ^a   Douglas, Stephen A ^d   Lambert, David G ^b   Calò, Girolamo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c GSK   (Italy)

^d GLAXOSMITHKLINE   (United States)

Author keywords

Ca 2+ i; Mouse plasma extravasation; Rat aorta; UFP 803; Urantide; Urotensin II; UT receptor

Indexed keywords

LIGAND; UFP 803; UNCLASSIFIED DRUG; URANTIDE; UROTENSIN; UROTENSIN II;

AORTA; ARTICLE; BIOASSAY; CELL STRAIN HEK293; CHO CELL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FLUOROMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REDUCTION; ROOM TEMPERATURE; TEMPERATURE DEPENDENCE;

ANIMALS; AORTA; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; LIGANDS; MICE; PEPTIDE FRAGMENTS; RATS; RECEPTORS, G-PROTEIN-COUPLED; UROTENSINS;

EID: 30344465324     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706438     Document Type: Article

References (30)

1. AFFOLTER, J.T., NEWBY, D.E., WILKINSON, I.B., WINTER, M.J., BALMENT, R.J. & WEBB, D.J. (2002). No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br. J. Clin. Pharmacol., 54, 617-621.
2. AMES, R.S., SARAU, H.M., CHAMBERS, J.K., WILLETTE, R.N., AIYAR, N.V., ROMANIC, A.M., LOUDEN, C.S., FOLEY, J.J., SAUERMELCH, C.F., COATNEY, R.W., AO, Z., DISA, J., HOLMES, S.D., STADEL, J.M., MARTIN, J.D., LIU, W.S., GLOVER, G.I., WILSON, S., MCNULTY, D.E., ELLIS, C.E., ELSHOURBAGY, N.A., SHABON, U., TRILL, J.J., HAY, D.W., OHLSTEIN, E.H., BERGSMA, D.J. & DOUGLAS, S.A. (1999). Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature, 401, 282-286.
3. BEHM, D.J., HEROLD, C.L., CAMARDA, V., AIYAR, N.V. & DOUGLAS, S.A. (2004). Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors. Eur. J. Pharmacol., 492, 113-116.
4. BOHM, F. & PERNOW, J. (2002). Urotensin II evokes potent vasoconstriction in humans in vivo. Br. J. Pharmacol., 135, 25-27.
5. CAMARDA, V., GUERRINI, R., KOSTENIS, E., RIZZI, A., CALO, G., HATTENBERGER, A., ZUCCHINI, M., SALVADORI, S. & REGOLI, D. (2002a). A new ligand for the urotensin II receptor. Br. J. Pharmacol., 137, 311-314.
6. CAMARDA, V., RIZZI, A., CALO, G., GENDRON, G., PERRON, S.I., KOSTENIS, E., ZAMBONI, P., MASCOLI, F. & REGOLI, D. (2002b). Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents. Naunyn-Schmiedeherg's Arch. Pharmacol., 365, 141-149.
7. CAMARDA, V., SONG, W., MARZOLA, E., SPAGNOL, M., GUERRINI, R., SALVADORI, S., REGOLI, D., THOMPSON, J.P., ROWBOTHAM, D.J., BEHM, D.J., DOUGLAS, S.A., CALO, G. & LAMBERT, D.G. (2004). Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors. Eur. J. Pharmacol., 498, 83-86.
8. CLOZEL, M., BINKERT, C., BIRKER-ROBACZEWSKA, M., BOUKHADRA, C., DING, S.S., FISCHLI, W., HESS, P., MATHYS, B., MORRISON, K., MULLER, C., NAYLER, O., QIU, C., REY, M., SCHERZ, M.W., VELKER, J., WELLER, T., XI, J.F. & ZILTENER, P. (2004). Pharmacology of the urotensin-II receptor antagonist ACT-058362: first demonstration of a pathophysiological role of the urotensin system. J. Pharmacol. Exp. Ther., 311, 204-212.
9. DOUGLAS, S.A., ASHTON, D.J., SAUERMELCH, C.F., COATNEY, R.W., OHLSTEIN, D.H., RUFFOLO, M.R., OHLSTEIN, E.H., AIYAR, N.V. & WILLETTE, R.N. (2000). Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J. Cardiovasc. Pharmacol., 36, S163-S166.
10. DOUGLAS, S.A., BEHM, D.J., AIYAR, N.V., NASELSKY, D., DISA, J., BROOKS, D.P., OHLSTEIN, E.H., GLEASON, J.G., SARAU, H.M., FOLEY, J.J., BUCKLEY, P.T., SCHMIDT, D.B., WIXTED, W.E., WIDDOWSON, K., RILEY, G., JIN, J., GALLAGHER, T.F., SCHMIDT, S.J., RIDGERS, L., CHRISTMANN, L.T., KEENAN, R.M., KNIGHT, S.D. & DHANAK, D. (2005). Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375. Br. J. Pharmacol., 145, 620-635.
11. DOUGLAS, S.A., DHANAK, D. & JOHNS, D.G. (2004). From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol. Sci., 25, 76-85.
12. DOUGLAS, S.A. & OHLSTEIN, E.H. (2000). Urotensin receptors. In: The IUPHAR Compendium of Receptor Characterization and Classification, ed. Girdlestone, D. pp. 365-372. London: IUPHAR Media.
13. DOUGLAS, S.A., TAYARA, L., OHLSTElN, E.H., HALAWA, N. & GIAID, A. (2002). Congestive heart failure and expression of myocardial urotensin II. Lancet, 359, 1990-1997.
14. GADDUM, J.H., HAMEED, K.A., HATHWAY, D.E. & STEPHENS, F.F. (1955). Quantitative studies of antagonists for 5-hydroxytryptamine. Q. J. Exp. Physiol. Cogn. Med. Sci., 40, 49-74.
15. GARTLON, J., PARKER, F., HARRISON, D.C., DOUGLAS, S.A., ASHMEADE, T.E., RILEY, G.J., HUGHES, Z.A., TAYLOR, S.G., MUNTON, R.P., HAGAN, J.J., HUNTER, J.A. & JONES, D.N. (2001). Central effects of urotensin-II following ICV administration in rats. Psychopharmacology (Berlin), 155, 426-433.
16. GENDRON, G., SIMARD, B., GOBEIL JR, F., SIROIS, P., DORLEANS-JUSTE, P. & REGOLI, D. (2004). Human urotensin-II enhances plasma extravasation in specific vascular districts in Wistar rats. Can. J. Physiol. Pharmacol., 82, 16-21.
17. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem., 260, 3440-3450.
18. GUERRINI, R., CAMARDA, V., MARZOLA, E., ARDUIN, M., CALO, G., SPAGNOL, M., RIZZI, A., SALVADORI, S. & REGOLI, D. (2005). Structure-activity relationship study on human urotensin II. J. Pept. Sci., 11, 85-90.
19. 2+] in whole cell suspensions using Fura-2. In: Calcium Signaling Protocols, ed. Lambert, D.G. 31-39. Totowa, NJ, U.S.A.: Humana Press.
20. ITOH, H., ITOH, Y., RIVIER, J. & LEDERIS, K. (1987). Contraction of major artery segments of rat by fish neuropeptide urotensin II. Am. J. Physiol., 252, R361-R366.
21. KENAKIN, T. (2004). A Pharmacology Primer. San Diego: Elsevier Academic Press.
22. MAGUIRE, J.J., KUC, R.E. & DAVENPORT, A.P. (2000). Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. J. Pharmacol., 131, 441-446.
23. MATSUMOTO, Y., ABE, M., WATANABE, T., ADACHI, Y., YANO, T., TAKAHASHI, H., SUGO, T., MORI, M., KITADA, C., KUROKAWA, T. & FUJINO, M. (2004). Intracerebroventricular administration of urotensin II promotes anxiogenic-like behaviors in rodents. Neurosci. Lett., 358, 99-102.
24. MICHELI, F., DI FABIO, R., CAVANNI, P., RIMLAND, J.M., CAPELLI, A.M., CHIAMULERA, C., CORSI, M., CORTI, C., DONATI, D., FERIANI, A., FERRAGUTI, F., MAFFEIS, M., MISSIO, A., RATTI, E., PAIO, A., PACHERA, R., QUARTAROLI, M., REGGIANI, A., SABATINI, F.M., TRIST, D.G., UGOLINI, A. & VITULLI, G. (2003). Synthesis and pharmacological characterization of 2,4-dicarboxypirroles as selective non-competitive mGLUR1 antagonists. Bioorg. Med. Chem., 11, 171-183.
25. PATACCHINI, R., SANTICIOLI, P., GIULIANI, S., GRIECO, P., NOVELLINO, E., ROVERO, P. & MAGGI, C.A. (2003). Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br. J. Pharmacol., 140, 1155-1158.
26. 2+]c: basic practical considerations. In: Calcium Signaling Protocols, ed. Lambert, D.G. pp. 3-30. Totowa, NJ, U.S.A.: Humana Press.
27. TOTSUNE, K., TAKAHASHI, K., ARIHARA, Z., SONE, M., ITO, S. & MURAKAMI, O. (2003). Increased plasma urotensin II levels in patients with diabetes mellitus. Clin. Sci. (London), 104, 1-5.
28. TOTSUNE, K., TAKAHASHI, K., ARIHARA, Z., SONE, M., SATOH, F., ITO, S., KIMURA, Y., SASANO, H. & MURAKAMI, O. (2001). Role of urotensin II in patients on dialysis. Lancet, 358, 810-811.
29. VERGURA, R., CAMARDA, V., RIZZI, A., SPAGNOL, M., GUERRINI, R., CALO, G., SALVADORI, S. & REGOLI, D. (2004). Urotensin II stimulates plasma extravasation in mice via UT receptor activation. Naunyn-Schmiedeberg's. Arch. Pharmacol., 370, 347-352.
30. WILKINSON, I.B., AFFOLTER, J.T., DE HAAS, S.L., PELLEGRINI, M.P., BOYD, J., WINTER, M.J., BALMENT, R.J. & WEBB, D.J. (2002). High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc. Res., 53, 341-347.